BC Week In Review | Apr 25, 2005
Company News

Innovate Oncology, Prostagenics LLC deal

IOVO acquired an exclusive worldwide license to develop and commercialize Prostagenics’ Capridine-Beta for cancer. IOVO is preparing an IND for a Phase I trial of the nitroacridine derivative in prostate cancer, but did not disclose...
Items per page:
1 - 1 of 1